Sorafenib - Bayer

Drug Profile

Sorafenib - Bayer

Alternative Names: BAY 43-9006 Tosylate; BAY 54-9085; BAY-43-9006; BAY-439006-Tosylate-Salt; Nexavar; Sorafenib tosilate; Sorafenib tosylate

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onyx Pharmaceuticals; University of Kentucky
  • Developer ACORN Research; Asan Medical Center; Bayer; Beth Israel Deaconess Medical Center; Charite of Berlin; Genentech; Indiana University; Indiana University School of Medicine; Karolinska University Hospital; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Center (Korea); National Cancer Institute (USA); Onyx Pharmaceuticals; Oregon Health & Science University; Takeda; Thomas Jefferson University; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Renal cell carcinoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Gastric cancer; Glioma; Head and neck cancer; Myelodysplastic syndromes; Neurofibromatoses; Oesophageal cancer; Ovarian cancer; Portal hypertension; Soft tissue sarcoma
  • Phase I Cancer; Urogenital cancer
  • Suspended Malignant melanoma; Prostate cancer
  • No development reported Acute promyelocytic leukaemia; Colorectal cancer; Germ cell and embryonal neoplasms; Neuroendocrine tumours; Pancreatic cancer; Solid tumours
  • Discontinued Breast cancer; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 01 Aug 2018 Memorial Sloan Kettering Cancer Center and Bayer completes a phase II trial in Oesophageal cancer (Metastatic disease, Recurrent) in USA (PO) (NCT00917462)
  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2018 Bayer terminates a phase II trial in Renal cell carcinoma (Combination therapy, Late-stage disease) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top